Subsequent studies have shown that combination therapy of BRAF and MEK inhibitors provides better outcomes than single agent of BRAF inhibitor for BRAFmut melanoma, becoming the current standard scheme [19, 20]. The gene discussed is MAP2K7; the disease is melanoma.